Apollomics Inc.
Foster City, CA · CIK 0001944885 · Biotech · Public
Humanized mouse models with patient-derived xenografts and human immune cells to test combination checkpoint inhibitor immunotherapies
cbtpharma.com →- Grants
- $320K
- 2 awards
- Sector median: 1
- Raised
- $10M
- 1 Form D · Aug 2026
- 2 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 15
- 3 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Combination Of Checkpoint Inhibitors | $160,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Combination Of Checkpoint Inhibitors | $160,000 | |
| Private capital raised | Form D · SEC | $10,000,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1856 | Dracen Pharmaceuticals, Inc. | — | $19M |
| 1857 | Ibex Investment Holdings II LLC | — | $1.0M |
| 1858 | Purinomia Biotech, Inc. | — | $10M |
| 1859 | Apollomics Inc. | — | $10M |
| 1860 | Syenex, Inc. | — | $8.9M |
| 1861 | SMSbiotech, Inc. | — | $16M |
| 1862 | Avotres Inc. | — | $8.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Diagnostic And Treatment Of Cancer Using C-met Inhibitorapplication
- Anti PD-L1 Antibodiesgranted
- Novel Pharmaceutical Formulation For C-met Inhibitorapplication
- Anti PD-1 Antibodiesgranted
- Novel ANTI-CD40 Antibodiesapplication
- Anti PD-1 Antibodiesgranted
- Cancer Treatment Using Combination Of Neutrophil Modulator With Modulator Of Immune Checkpointapplication
- Treatment Of Cancer Resistant To Egfr Tki Using C-met Inhibitorapplication
- Treatment Of Cancer Resistant To Egfr Tki Using C-met Inhibitorapplication
- Treatment Of Cancer Resistant To Egfr Tki Using C-met Inhibitorapplication
- Diagnostic And Treatment Of Cancer Using C-met Inhibitorapplication
- Novel Pharmaceutical Formulation For C-met Inhibitorapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.